Management of the hypertensive patient with coronary insufficiency but without atherosclerosis

Current Opinion in Cardiology

Volumn 18, Issue 4, 2003, Pages 255-259

  Preik, Michael ^a   Kelm, Malte ^a   Strauer, Bodo Eckehard ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Arterial hypertension; Coronary flow reserve; Hypertensive heart disease

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; ISRADIPINE; LISINOPRIL; LOSARTAN; PERINDOPRIL; VERAPAMIL;

ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; ELECTROCARDIOGRAM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MICROVASCULATURE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANTIHYPERTENSIVE AGENTS; CORONARY CIRCULATION; CORONARY DISEASE; HUMANS; HYPERTENSION; RISK ASSESSMENT; VENTRICULAR FUNCTION, LEFT;

EID: 0042381813     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200307000-00003     Document Type: Review

References (43)

1. World Health Organization. International society of hypertension guidelines for the management of hypertension. J Hypertens 1999, 17:151-183.
2. Slama M, Susic D, Frohlic ED: Prevention of hypertension. Curr Opin Cardiol 2002, 17:531-536.
3. He KKL, Pinsky JC, Kannel WB, et al.: The epidemiology of heart failure. The Framingham Study. J Am Coll Cardiol 1993, 22:6A-13A.
4. Motz W, Vogt M, Rabenau O, et al.: Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms. Am J Cardiol 1991, 68:996-1003.
5. Strauer BE: The significance of coronary reserve in clinical heart disease. J Am Coll Cardiol 1990, 15:775-783.
6. Burke AP, Farb A, Liang Y, et al.: Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circulation 1996, 94:3138-3145.
7. Strauer BE, Schwartzkopff B, Kelm M: Assessing the coronary circulation in hypertension. J Hypertens 1998, 16:1221-1233.
8. Schwartzkopff B, Motz W, Frenzel H, et al.: Structural and functional alter ations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993, 88:993-1003.
9. Muiesan ML, Rizzoni D, Salvetti M, et al.: Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens 2002, 20:1439-1444.
10. Hyndman ME, Parsons HG, Verma S, et al.: The T-786-C mutation in endothelial nitric oxide synthase is associated with hypertension. Hypertension 2002, 39:919-922.
11. Zeiher AM, Krause T, Schächinger V, et al.: Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 1995, 91:2345-2352.
12. Mohri M, Ichiki T, Hirooka Y, et al.: Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy. Am Heart J 2002, 143:684-689.
13. Maffei A, Poulet R, Vecchione C, et al.: Incresed basal nitric oxide release despite enhanced free radical production in hypertension. J Hypertens 2002, 20:1135-1142.
14. Hamilton C: Nitric oxide, oxidative stress and hypertension: a complex equation. J Hypertens 2002, 20:1055-1056.
15. Higashi Y, Sasaki S, Nakagawa K, et al.: Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002, 346:1954-1962.
16. Muiesan ML, Salvetti A, Rizzoni D et al.: Association of changes in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995, 13:1091-1095.
17. Jennings GL, Dilley RJ: Left ventricular remodelling impacts on coronary flow reserve in hypertensive patients: Is there a vascular mechanism? J Hypertens 2002, 20:1291-1293.
18. Galderisi M, Cicala S, Case P, et al.: Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension. Am J Cardiol 2002, 90:860-864.
19. Lee AJ: Haemorheological, platelet and endothelial factors in essential hypertension; (Commentary). J Hum Hypertens 2002, 16:529-531.
20. Cuspidi C, Ambrosioni E, Mancia G, et al.: APROS Investigators: Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the assessment of prognostic risk observational survey. J Hypertens 2002, 20:1307-1314. A large cohort study about the value of ultrasound assessment of the heart and carotid wall to obtain a more valid assessment of global cardiovascular risk in hypertensive patients.
21. Slama M, Susic D, Varagic J, et al.: Diastolic dysfunction in hypertension. Curr Opin Cardiol 2002, 17:368-373.
22. Schillaci G, Pasqualini L, Verdecchia P, et al.: Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002, 39:2005-2011.
23. Dell'Omo G, Penno G, Giorgi D, Di Bello V, Mariani M, Pedrinelli R: Association between high-normal albuminuria and risk factors for cardiovascular andrenal disease in essential hypertensive men; (Original investigations: Pathogenesis and treatment of kidney disease and hypertension). Am J Kidney Dis 2003, 40:1-8.
24. Redon J, Williams B: Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002, 20:353-355.
25. Higashi Y, Nakagawa K, Kimura M, et al.: Circadian variation of blood pressure and ensothelial function in patients with essential hypertension: a comparison of Dippers and Non-Dippers. J Am Coll Cardiol 2002, 40:2039-2043.
26. Yuda S, Short L, Leano R, et al.: Myocardial abnormalities in hypertensive patients with normal and abnormal left ventricular filling: a study of ultrasound tissue characterization and strain. Clin Sci 2002, 103:283-293.
27. Taddei S, Salvetti A: Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens 2002, 20:1671-1674.
28. Motz W, Strauer BE: Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension 1996, 27:1031-1038.
29. Fragasso G, Lu C, Dabroski P, et al.: Comparison of stress/rest myocardial perfusion tomography, dipyridamole and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. J Am Coll Cardiol 1999, 34:441-447.
30. Picano E, Palinkas A, Amyot R: Diagnosis of myocardial ischemia in hypertensive patients. J Hypertens 2001, 19:1177-1183.
31. Bartel T, Yang Y, Müller S, et al.: Noninvasive assessment of microvascular function in arterial hypertension by transthoracic doppler harmonic echocardiography. J Am Coll Cardiol 2002, 39:2012-2018. An important study showing that transthoracic Doppler harmonic echocardiography is suitable to assess microvascular dysfunction corresponding well to invasive measurements
32. Foltz WD, Huang H, Fort S, et al.: Vasodilator response assessment in porcine myocardium with magnetic resonance relaxometry. Circulation 2002, 106:2714-2719.
33. Ibrahim T, Nekolla SG, Schreiber K, et al.: Assessment of coronary flow reserve: comparison between contrast-enhanced magnetic resonance imaging and positron emission tomography. J Am Coll Cardiol 2002, 39:864-870.
34. Olsen MH, Wachtell K, Hermann KL, et al.: Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Am Heart J 2002, 144:530-537.
35. Grandi AM, Imperiale D, Santillo R, et al.: Aldosteron antagonist improves diastolic function in essential hypertension. Hypertension 2002, 40:647-652.
36. Yusuf S, Sleight P, Pogue J, et al.: Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
37. Dahlof B, Devereux RB, Kjeldsen S, et al.: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:995-1003. A large cohort randomized trial demonstrating that losartan is more effective than atenolol in reducing cardiovascular morbidity and mortality in patients with arterial hypertension.
38. Brilla CG, Janicki JS, Weber RT: Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991, 83:1771-1779.
39. Schwartzkopff B, Brehm M, Mundhenke M, et al.: Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000, 36:220-225.
40. Akinboboye OO, Chou R-L, Bergmann SR: Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists. J Am Coll Cardiol 2002, 40:703-709.
41. Schiffrin EL, Park JB, Pu Q: Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 2002, 20:71-78.
42. Sica DA, Elliott WL: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in combination: theory and practice. J Clin Hypertens 2002, 3:383-387.
43. Duprez D, De Buyzere M, Rietzschel E: Aldosterone and vascular damage. Curr Hypertens Rep 2000, 2:327-334.